Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
83%(5 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

terminated114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

NCT07235033
completedphase_1

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

NCT04321252
completedphase_2

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

NCT03334747
terminatedphase_1

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

NCT02543086
completedphase_2

A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

NCT01836458
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07235033Phase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

Completed
NCT04321252Phase 1

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

Completed
NCT03334747Phase 2

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

Completed
NCT02543086Phase 1

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Terminated
NCT01836458Phase 2

A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

Completed
NCT01860989Phase 2

A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection

Completed
NCT01524341Phase 2

Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7